The present invention relates to compounds of formula (I)
1
The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
A variety of penta-2,4-dienyl- and pent-2-en-4-ynylindium reagents have been prepared in situ from the reaction of the corresponding allylic bromides with indium metal, and their reactions with carbonyl compounds have been examined. The reaction with aldehydes gives the corresponding homoallyl alcohols in high yields. The coupling occurs regioselectively at the γ-position of these indium reagents. No
Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders
申请人:——
公开号:US20030199451A1
公开(公告)日:2003-10-23
The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-&agr;/PPAR-&ggr;) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.